实用医学杂志Issue(24)：3946-3948,3.DOI:10.3969/j.issn.1006-5725.2014.24.023
性别影响利妥昔单抗治疗弥漫大B细胞淋巴瘤
Gender affects the curative effect of rituximab for treatment of diffuse large B cell lymphoma
刘洋 1刘景华 2刘彦琴 1王吉刚 1白颖 1周凡1
作者信息
- 1. 110016 沈阳军区总医院血液科
- 2. 辽宁医学院
- 折叠
摘要
Abstract
Objective To study the effect of gender on the curative effect of rituximab for the treatment of diffuse large B cell lymphoma with five-year progression-free survival. Methods The clinical and laboratorial data of 155 diffuse large B cell lymphoma patients from January 2003 to January 2011 were retrospectively analyzed. The patients were divided it into R-CHOP group and CHOP group according to if rituximab was used, and then subdivided based on their gender into R-CHOP-M, R-CHOP-F groups and CHOP-M, CHOP-F groups, respectively. Kaplan-Meier survival curve was plotted for the progression-free survival. Results The five-year progression-free survival rate in the R-CHOP group was higher than the CHOP group, and the rate of R-CHOP-F group was higher than R-CHOP-M group, but there were no significant differences between the CHOP-M group and the CHOP-F group. The rate of the R-CHOP-M group was a little bit higher than the CHOP-M group with no statistical significance. The rate of the R-CHOP-F group was higher than CHOP-F group. Conclusion Rituximab is beneficial for female than for male, which may contribute to the adjustment of drug doses if a male is treated with rituximab.关键词
弥漫大B细胞淋巴瘤/利妥昔单抗/性别/无进展生存Key words
Diffuse large B cell lymphoma/Rituximab/Gender/Progression-free survival引用本文复制引用
刘洋,刘景华,刘彦琴,王吉刚,白颖,周凡..性别影响利妥昔单抗治疗弥漫大B细胞淋巴瘤[J].实用医学杂志,2014,(24):3946-3948,3.
